Pathfinder Cell Therapy (PFND) Inactive 10-K2009 FY Annual report

Filed: 22 Mar 10, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: Arabia, ASC, ASU, authoritative, Baxter, began, breakdown, broadly, Clubb, Codification, codified, comment, conduit, correction, CoSeal, Costa, CryoLife, deliverable, Eastern, engraftment, explicitly, filer, GAAP, geographic, growing, India, Integra, interim, maximize, Middle, modification, orphan, pronouncement, provision, pursuit, qualitative, quantitative, Raptor, reliable, retrospective, Rica, Saudi, session, source, stem, superseded, Taiwan, Tarix, thrombocytopenia, Topic, understanding, updated, variable

Removed: area, Assistant, CEO, collaborative, deemed, dilutive, favorable, furniture, intellectual, investing, Irving, launched, mehmet, oz, property, receiving, remaining, resolution, St, stage, strategy, subsidiary, tested, ultimately

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

PFND similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-147184, 333-146493 and 333-19195) and Form S-8 (Registration Nos. 33-60580, 333-03895, 333-95127, 333-95129, 333-91386 and 333-134608) of SyntheMed, Inc. (the "Company") of our report (which included an explanatory paragraph relating to the Company's ability to continue as a going concern) dated March 19, 2010 relating to the financial statements, which appears in this Form 10-K.

/s/ EISNER LLP

New York, New York

March 19, 2010